Why the study?
The management of subclinical atrial fibrillation detected by cardiac implantable electronic devices, particularly regarding oral anticoagulation, remains controversial.
Does oral anticoagulation reduce complications in patients with subclinical atrial fibrillation detected by CIEDs?
Does oral anticoagulation reduce complications in patients with subclinical atrial fibrillation detected by CIEDs?
Management of subclinical atrial fibrillation requires individualized decision-making regarding oral anticoagulation to balance stroke and bleeding risks.
Subclinical atrial fibrillation (SCAF) episodes are frequently detected in patients with cardiac implantable electronic devices (CIEDs). These asymptomatic arrhythmias are increasingly recognized as potential harbingers of clinical atrial fibrillation and thromboembolic events. However, the management of SCAF-particularly regarding the use of oral anticoagulation (OAC)-remains controversial. This literature review (Medline, Scopus, Goggle scholar, Embase) focuses on using current literature and clinical studies to guide decision-making regarding anticoagulation therapy and other treatment options that can limit complications for patients with SCAF. The decision to initiate anticoagulation in patients with atrial high-rate episodes (AHREs) should be individualized, balancing stroke risk against bleeding potential. Ongoing research and post hoc analyses will further clarify which subgroups may benefit most from therapy, informing future guideline recommendations.
No takes yet. Share an insight, caveat, or question.
Alhwarat et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: